Technology

Paratek Pharmaceuticals

$6.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.31 (+4.88%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell PRTK and other stocks, options, and ETFs commission-free!

About PRTK

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA. The listed name for PRTK is Paratek Pharmaceuticals, Inc. Common Stock.

CEO
Evan Loh
Employees
102
Headquarters
Boston, Massachusetts
Founded
1996
Market Cap
314.98M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
379.63K
High Today
$6.67
Low Today
$6.05
Open Price
$6.29
Volume
378.46K
52 Week High
$7.27
52 Week Low
$2.50

Collections

PRTK Earnings

-$1.16
-$0.77
-$0.39
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 23, After Hours

You May Also Like

USIO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure